Kornimate/medical-research-clean huggingface dataset:
a novel virtual reality task in parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of this study is to compare experiences and effects of a virtual reality physical program to an in-person rock steady boxing program. people with parkinson's disease, age 18 and up, who participate in rock steady boxing weekly may join this study.

if you agree to be in this study, we will ask you to do the following things: provide basic information about yourself, complete tests of thinking on the computer and in person, participate in your regular rock steady boxing, and for three weeks replace your rock steady boxing with a virtual reality game done with a headset. you will work independently with a study team member. * visit 1 or visit 1 and 2 if split up: beginning measures/demographics, parkinson's disease symptoms, cognition (about 45 minutes), vr training (30 minutes) or regular rock steady boxing (1 hour) * visit 2-5: virtual reality training (30 minutes or regular rock steady boxing (1 hour) * visit 6: virtual reality training (30 minutes) or regular rock steady boxing (1 hour), cognitive measures (about 20 minutes) * visit 7: cognitive measures (about 20 minutes), virtual reality training (30 minutes) or regular rock steady boxing (1 hour); intrinsic motivation inventory (5 minutes) * visit 8-11: virtual reality training (30 minutes) or regular rock steady boxing (1 hour) * visit 12 or visit 13 if baseline was split up: virtual reality training (30 minutes) or regular rock steady boxing (1 hour), cognitive measures (20 minutes), intrinsic motivation inventory (5 minutes), end of study survey (5-10 minutes)

Eligibility criteria:
inclusion criteria: * diagnosed with parkinson's disease * age 18+ years * currently involved in rock steady boxing * willing to participate 2-3 days/week exclusion criteria: * known history of movement-induced vertigo * other cognitive or movement disorders
impact of passive heat on metabolic, inflammatory and vascular health in persons with spinal cord injury

Conditions: Spinal Cord Injury; Chronic Inflammation; Glucose Metabolism; Endothelial Function

Summary: sci results in higher incidence of heart disease and diabetes and heart disease is the most common cause of death. chronic inflammation, deleterious changes in vascular structure and impaired glucose metabolism are risk factors that contribute to both heart disease and diabetes. while exercise can help reduce these risk factors, paralysis and impaired accessibility often precludes exercise in persons with sci. new research in able-bodied persons demonstrates passive heating decreases inflammation and improves vascular function. similar studies in persons with sci suggest they may also have the same health benefits however these studies only investigated the impact of short term (one episode) passive heating (as opposed to repeated bouts). repeated bouts of heat exposure will likely be required to impact chronic inflammation, but this has never been tested in persons with sci. this study will test the impact of repeated bouts (3x/week) of passive heat stress over a longer term (8 weeks) on inflammation, metabolism and vascular function.


Eligibility criteria:
inclusion criteria: * stable sci over 1 year of duration exclusion criteria: * persons who smoke cigarettes * daily administration of anti-inflammatory medications * daily administration of vasoactive medications * pressure ulcer stage 3 or 4 * history of heat related illness

Keywords: spinal cord injury
effect of natural compounds on the severity of hpv-induced cervical lesions

Conditions: Papilloma; Cervix Lesion

Summary: to test the efficacy of a newly-commercialized formula, 40 hpv-positive women displaying chronic cervicitis, mild dysplasia or moderate dysplasia. women in the study group took one tablet per day containing 200 mg of egcg, 400 mcg of folic acid, 1 mg of vitamin b12 and 50 mg of hyaluronic acid for twelve weeks. women in the control group received no treatment.


Eligibility criteria:
inclusion criteria: * hpv infections * occurrence of low-grade cervical lesions exclusion criteria: * diagnosis of malignancy or severe cervical lesions * concurrent uterine pathologies * pregnancy or intended to seek pregnancy in the next three months * cancer
improving medical training for the care of chronic conditions

Conditions: Diabetes Mellitus

Summary: while medical training has increasingly included chronic care management, quality care necessitates education approaches that go farther. in april 2005, the louis stokes cleveland veterans affairs medical center (vamc) implemented a weekly diabetes shared medical appointment (sma). smas offer an important opportunity to improve chronic care and a unique setting for training physicians. in order to equip physicians with needed resources to manage chronic care, the ways in which sma experiences are processed and integrated into learning about interdisciplinary approaches and expanding trainees' understanding of chronic care issues need to be examined.

: most physicians receive training in and about an acute care-oriented health care system that cannot adequately address the challenges of chronic care management. while medical training has increasingly included chronic care management, quality care necessitates education approaches that go farther. in april 2005, the louis stokes cleveland vamc implemented a weekly diabetes shared medical appointment (sma). results indicate that smas are sustained and, as such, smas offer an important opportunity to improve chronic care and a unique setting for training physicians. smas offer the potential to provide training in crucial skills that have to date remained less amendable to traditional educational practices. in order to equip physicians with resources to effectively and efficiently manage chronic care, the ways in which sma experiences are processed and integrated into learning about interdisciplinary approaches and expanding trainees' understanding of chronic care issues need to be examined. without addressing this gap, it is not possible to develop a comprehensive care model that links education and patient outcomes for chronic conditions, such as diabetes. building on previous pilot work, we continued to address evaluating and validating instruments. the proposed pilot project included using a think-aloud protocol to evaluate and validate new items and scales assessing interdisciplinary team and chronic care/diabetes beliefs, and evaluating and adjusting direct observation coding tools for chronic condition care.

Eligibility criteria:
inclusion criteria: medical students: inclusion: all medical students participating in diabetes shared medical appointment sessions or other training experiences during the course of the study. exclusion criteria: medical students who have participated in smas for patients with diabetes at the cleveland vamc in the past.

Keywords: shared medical appointments diabetes education
resistant starch supplementation effects on the intestinal tract profile and cardiovascular markers in renal patients

Conditions: Chronic Kidney Disease; Hemodialysis; Non-dialysis Patients

Summary: the objective of this study is to assess whether supplementation with resistant starch from the rice-flour coffee developed by embrapa, as well as from an already industrialized product (hi-maize of ingredion®) could modulate the intestinal microbiota of patients with ckd ( both patients under conservative treatment, such as dialysis treatment), as well as exerting a beneficial effect with respect to reducing levels of inflammatory markers of oxidative stress, uremic toxins and in addition, markers of cardiovascular disease.

patients with chronic kidney disease (ckd), especially those who are on dialysis have a high prevalence of cardiovascular mortality and, among the risk factors include inflammation and oxidative stress. recently this scenario, beyond those alterations found in these patients, it has been suggested that the balance of the intestinal flora in these patients might be a new factor of cardiovascular risk. some treatment strategies have been studied in order to modulate the gut microbiota as the use of pre, pro or synbiotics. although few studies, supplementation with prebiotics has been recommended. however, the use of resistant starch as a source of prebiotic for modulation of the intestinal flora in these patients has not yet been evaluated, but the study of prof. vaziri the university of california irvine, usa, with nephrectomized rats showed that the resistant starch was able to attenuating the progression of failure of renal function, inflammation and oxidative stress and minimize the abnormalities of intestinal epithelial barrier. the objective of this study is to assess whether supplementation with resistant starch from the rice-flour coffee developed by embrapa, as well as from an already industrialized product (hi-maize of ingredion®) could modulate the intestinal microbiota of patients with ckd ( both patients under conservative treatment, such as dialysis treatment), as well as exerting a beneficial effect with respect to reducing levels of inflammatory markers of oxidative stress, uremic toxins and in addition, markers of cardiovascular disease.

Eligibility criteria:
inclusion criteria: * hemodialysis patients with arteriovenous fistula as vascular access in the upper limb and on maintenance dialysis for at least 6 months; * patients under conservative treatment in stages 3a and 3b (30 to 60 ml / min) of chronic kidney disease and receiving nutritional treatment for at least 6 months (adequate supply of energy 30-35kcal/kg/day and hypoproteic 0.6 g/kg/day. exclusion criteria: * patients with autoimmune and infectious diseases, diabetes, cancer and aids; * patients with catheter for hemodialysis access; * patients using catabolizing drugs, supplements as antioxidant vitamin, probiotics, prebiotics, synbiotics and antibiotics. * patients who exercise are also deleted.

Keywords: chronic kidney disease hemodialysis conservative treatment resistance starch
rhabdomyolysis - a study of patients and laboratory values to guide treatment

Conditions: Rhabdomyolysis

Summary: rhabdomyolysis is a potentially life-threatening syndrome characterized by breakdown of skeletal muscle, and leakage of intracellular substances such as myoglobin and creatine kinase (ck) into the circulation. the aetiological spectrum of rhabdomyolysis is extensive, and the clinical spectrum varies from a transient subclinical increase in ck activity to acute kidney injury (aki) as a serious complication. there are no large prospective studies and only a few retrospective studies on rhabdomyolysis.

rhabdomyolysis is a potentially life-threatening syndrome characterized by breakdown of skeletal muscle, and leakage of intracellular substances such as myoglobin and creatine kinase (ck) into the circulation. the aetiological spectrum of rhabdomyolysis is extensive, and the clinical spectrum varies from a transient subclinical increase in ck activity to acute kidney injury (aki) as a serious complication. there are no large prospective studies and only a few retrospective studies on rhabdomyolysis. the project will give much needed information about incidence, aetiologies and the clinical course of rhabdomyolysis. the main objective will be to study rhabdomyolysis with focus on the development of aki and how laboratory values can guide treatment, and thus act as basis for guidelines. more knowledge is needed about rhabdomyolysis and long-term kidney injury, and the study will aim to identify a risk population for later kidney injury, thus being able to refer this group to follow-up and prevent further injury. on the other hand, exercise-induced rhabdomyolysis patients are probably hospitalized more than necessary these days, and over-treatment could be prevented if better guidelines were obtained. the possible cardiotoxicity of myoglobin needs further study, and would benefit the patient group but also fill a knowledge gap for the clinicians. therefore, this project will ideally obtain new knowledge for the health services, potentially improve existing practice and fill important knowledge gaps.

Eligibility criteria:
1. main study: * inclusion criteria: patients age 18 years and older, with a muscle injury developed before hospitalization and serum ck activity ≥5000 u/l and/or serum myoglobin concentrations ≥1000 ng/ml within 72 hours after admission will be included. * exclusion criteria: patients with unknown identity will be excluded. 2. sub-study on rhabdomyolysis and cardiac enzymes: * inclusion criteria: all patients with troponins over 14 ng/l and who otherwise fulfills the inclusion criteria can be included. * exclusion criteria: acute coronary syndrome, heart failure, arrythmia, previous myocarditis, circulatory shock, acute pulmonary embolism, thoracic trauma/heart trauma or ckd before hospitalization.
effect of probiotic lactobacilli on vaginal flora of pregnant women at high risk for preterm delivery

Conditions: Premature Birth; Bacterial Vaginosis

Summary: purpose of the study is to determine the effect of probiotic lactobacilli on the vaginal flora and cytokine profile during pregnancy, and the incidence of preterm labour in women at high risk for preterm birth.

preterm labour involves multiple causes - one of the most significant factors being a prior history of preterm birth. infection is another major cause of preterm labour (ptl) and is estimated to cause up to 30% of ptl. bacterial vaginosis (bv) is an alteration in the endogenous vaginal microflora preceded by a decreased presence of lactobacilli species and increased growth of gardnerella and other pathogens. bv is a strong risk factor for ptl, and is associated with a 40% increased risk in some populations. initial studies suggested that the treatment of bv with antibiotics could decrease the incidence of ptl, but this has not been confirmed by randomized trials. there is substantial evidence that the "normal" lactobacillus dominated urogenital microflora play an important role in maintenance of a healthy urinary and reproductive tract. one hundred and sixty (160) women at high risk for ptl, based on a prior history of preterm birth, will be approached at their first antenatal visit to participate. recruitment of 54 patients with symptomatic or asymptomatic bv (based on nugent scoring). women with documented bv will be randomized to either treatment with lactobacilli preparation (n=27) or placebo (n=27). women with symptomatic bv will be treated with oral metronidazole prior to starting the lactobacilli or placebo. none of the subjects, researchers or clinical staff will know which preparation each woman receives. this study will be the first to examine the ability of lactobacilli preparations to maintain a normal vaginal flora in pregnant women. in addition, the results will potentially serve as the basis for a multi-centre rct to determine efficacy of this treatment in preventing preterm birth.

Eligibility criteria:
inclusion criteria: * pregnant women with previous incidence of preterm labour * otherwise healthy * over 18 years of age * able to provide informed consent * less than or equal to 16 weeks gestation * singleton pregnancy * normal uterine cavity exclusion criteria: * significant medical complications (preeclampsia, thrombophilia, hypertension) * multiple pregnancy * less than 18 years of age * patients receiving antibiotics or other antimicrobial therapies at time of recruitment * fetal complications such as intrauterine growth restriction or other abnormalities * diabetes * documented need for cervical cerclage * patient enrolled in other clinical trials
a study to evaluate the long-term safety and efficacy of lbec0101 in subjects with active ra despite methotrexate (mtx)

Conditions: Rheumatoid Arthritis

Summary: to evaluate the long-term safety including immunogenicity and efficacy of lbec0101 50 mg subcutaneous weekly injection when co-administered with mtx

this study is to evaluate the long-term safety including immunogenicity and efficacy of lbec0101 50 mg subcutaneous weekly injection when co-administered with mtx for additional 48 weeks (a total of 100 weeks including 52 weeks of the treatment period in study lg-eccl002) in the subjects who have completed the treatment period of phase iii clinical study for lbec0101 (study no. lg-eccl002).

Eligibility criteria:
inclusion criteria: * patients who completed the treatment period of study lg-eccl002 * patients requiring continuous treatment for rheumatoid arthritis upon the investigator's discretion * for childbearing female patients or surgically non-sterile male patients, those who agreed to avoid pregnancy using proper contraceptive methods during the study. * patients who made a voluntary decision to participate in this clinical study and gave a voluntary written consent to comply with all the instructions with full understanding after being informed of the study exclusion criteria: * patients deemed difficult to participate in this extension study due to the adverse events which occurred in study lg-eccl002, upon the investigator's discretion at screening * patients with at least 10 swollen joints (out of the total 66 assessing joints) or at least 12 tender joints (out of the total 68 assessing joints) at screening * women in pregnancy or lactation, or patients planning to be pregnant during the study period * patients ineligible for this clinical study upon the investigator's discretion
a pilot trial using br55 ultrasound contrast agent in the assessment of prostate cancer

Conditions: Prostate Cancer

Summary: pilot study to evaluate the ability of br55 to identify prostate cancer lesions with gleason score ≥7 by ultrasound molecular imaging on the basis of a visual score in comparison with histopathology results

this multi-centre, open label, prospective, pilot study was designed to assess the ability of br55 to detect vegfr2 in human prostate cancer by ultrasound molecular imaging (usmi). the binding of br55 to vegfr2 (focal enhancement still visible after significant decrease in signal from circulating microbubbles seen) was assessed at usmi and vegfr2 expression was to be confirmed by immunohistochemistry (ihc) analysis including vegfr2 and cd31 staining.

Eligibility criteria:
inclusion criteria: * male, age between 50-70 years old * increased prostate-specific antigen (psa) level \>4 ng/ml * known prostate cancer * scheduled for prostatectomy not earlier than 3 days and not later than 30 days following br55 administration (with the exception of training cases where this requirement is not applicable) * provided written informed consent and willing to comply with protocol requirements exclusion criteria: * documented acute prostatitis or urinary tract infections * known to suffer from stable angina pectoris and/or proven coronary disease, or have symptoms suspicious of coronary disease * history of any clinically unstable cardiac condition including class iii/iv cardiac failure or right-to left shunts * severe cardiac rhythm disorders within the last 7 days * severe pulmonary hypertension or uncontrolled systemic hypertension or respiratory distress syndrome * received a prostate biopsy procedure within 30 days before admission into the study * determined by investigator to be clinically unsuitable for the study * participated in a concurrent clinical trial or has participated in another clinical trial with an investigational compound within the past 30 days

Keywords: prostate cancer ultrasound imaging
a study to compare the pharmacokinetics and safety of optivate® and haemate p® in patients with von willebrand disease.

Conditions: vonWillebrand's Disease

Summary: the main objectives of the study were * to compare the pharmacokinetics (pk) of optivate® and haemate p® in various types of vonwillebrand disease (vwd) using the results from the vwf: rco, vwf:ag, vwf:cba and factor viii assays. * to compare the clinical tolerance and safety of these two treatments after single iv infusions in subjects with vwd.


Eligibility criteria:
inclusion criteria: * previously treated subjects of at least 12 years of age, with any type of vwd were eligible for entry into this study. exclusion criteria: -
thrombophilic risk factors in pediatric patients diagnosed at the ha'emek medical center

Conditions: Thrombosis

Summary: the study will assess the clinical and laboratory data of about 100 pediatric patients diagnosed and treated at the pediatric hematology unit during the years 1980 until 2007 because of thrombotic events. the results, the treatment given, and the outcome of the patients will be summarized.


Eligibility criteria:
inclusion criteria:all the patients diagnosed since 1980. exclusion criteria:patients with insufficient data records.

Keywords: factor v leiden prothrombin mutation hypercoagulability pediatrics
pet-mri for functional imaging of the testis: a feasibility study

Conditions: Infertility; Non-obstructive Azoospermia; Vasectomy

Summary: the primary objective of this study is to explore feasibility of testis functionality assessment and testis imaging obtained from positron emissions tomography (pet) /magnetic resonance imagine (mri). using advanced mri metrics, investigators will study the three-dimensional structure of normal testis, the levels of specific elements and compounds in the tissues (which can only be found via these imaging techniques), and the directionality (and alterations in directionality) of tissue structure. investigators hope to develop hypothesis that will in turn suggest bio-markers to be explored in subsequent clinical trials.


Eligibility criteria:
inclusion criteria: * men with proven paternity desiring vasectomy who are over 18 years of age. exclusion criteria: * bilaterally absent testes, unilaterally or bilaterally undescended testes * patients who have proven azoospermia or no proven paternity * inability to tolerate mri including conditions such as claustrophobia or inability to lay flat for \> 45 minutes. * presence of pacemaker/iimplantable cardioverter defibrillator (icd) or perfusion pumps * ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial heart, valves with steel parts, metal fragments, shrapnel, bullets, tattoos near the eye, or steel implants. * substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study * all women are excluded as such patients do not have the relevant anatomy being considered in this study * anyone from a vulnerable population will be excluded from the study

Keywords: testis spermatogenesis